Previous 10 | Next 10 |
The stock market is giving investors some real healthcare bargains right now. In this Fool.com roundtable, we present bullish views on a couple of NASH stocks that have been hammered. And we give some love to an under-the-radar COVID play that is super cheap right now. Here's why our te...
GlaxoSmithKline (NYSE:GSK) Vir Biotechnology (NASDAQ:VIR) said preclinical data suggested that their COVID-19 therapy sotrovimab retained neutralizing activity against the BA.2 subvariant of Omicron. The companies will share the pseudovirus results with government and regulatory aut...
– Pseudovirus results being shared with government and regulatory authorities; publication in bioRxiv anticipated in the coming week; additional live virus testing underway – SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: V...
Immunome (NASDAQ:IMNM) said in vitro data showed effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two external laboratories (Boston University’s National Emerging Infectious Diseases Laboratories and Wa...
Vir Biotechnology (NASDAQ:VIR) appointed Johanna Friedl-Naderer as executive vice president and chief business officer, Global, effective March 2, 2022. Prior to joining Vir, Friedl-Naderer was President of Europe, Canada & Partner Markets for Biogen, where she served on the companyȁ...
SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global, effective March 2, 2022. Reporting to Vir’s Chief Executive Officer...
GlaxoSmithKline is one of the eight largest pharmaceutical companies in the world. The company's revenue continues to grow QoQ with a 9.3% increase in Q3 2021 compared to Q2 2021. Vaccine sales were £2,174 million in Q3 2021, up 38.4% from Q2. Sales of Sotrovimab for COVID-19...
If your New Year's resolutions included becoming wealthier, turning to the stock market is a great way to accomplish that goal. Since the S&P 500 recovered from the market crash in early 2020, it has more than doubled despite lingering economic woes. Investing in great companies...
– New commitment from the Bill & Melinda Gates Foundation supports the development of Vir’s novel “vaccinal antibody” technology as another important step in the fight to address global infectious diseases – SAN FRANCISCO, Jan. 13, 20...
– If authorized, would provide the option for intramuscular administration of sotrovimab, in addition to currently authorized intravenous administration – – Submission follows COMET-TAIL Phase 3 data demonstrating that intramuscular administration...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...